<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02617485</url>
  </required_header>
  <id_info>
    <org_study_id>MabionCD20-002NHL</org_study_id>
    <nct_id>NCT02617485</nct_id>
  </id_info>
  <brief_title>MabionCD20® Compared to MabThera® in Lymphoma Patients</brief_title>
  <official_title>Randomized, Parallel-group, Double-blind, Comparative Bioequivalence Trial of MabionCD20 (Mabion SA) Compared to MabThera (Rituximab by Hoffman-La Roche) in Patients With Diffuse Large B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mabion SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mabion SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to demonstrate the high level of biosimilarity between MabionCD20
      (MABION SA) and the reference product: MabThera (rituximab by Hoffman-La Roche) in patients
      with CD20-positive diffuse large B-cell lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who meet criteria for participation in this study receive 8 intravenous infusions of
      MabionCD20® or MabThera® 21 days interval in combination with standard dosage regimen of
      CHOP. The duration of the study is 12 months. The treatment and observation period will last
      26 weeks starting from Day 1, until Week 26 - one month after last IMP infusion.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration- time curve from time zero to final time point</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration- time curve from time zero to final time point</measure>
    <time_frame>26 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Diffuse Large B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>MabionCD20®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A course of MabionCD20® consists of intravenous infusions in dose 375 mg/m2 body surface area, administered on day 1 of each chemotherapy cycle for 8 cycles.
Intervention: Drug: Rituximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MabThera®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A course of MabThera® consists of intravenous infusions in dose 375 mg/m2 body surface area, administered on day 1 of each chemotherapy cycle for 8 cycles.
Intervention: Drug: Rituximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m2 IV on day 1 of each 21 days chemotherapy cycle. Number of Cycles: 8.</description>
    <arm_group_label>MabionCD20®</arm_group_label>
    <arm_group_label>MabThera®</arm_group_label>
    <other_name>MabThera®, MabionCD20®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>50 mg of doxorubicin per square meter administrated IV on day 1 of each chemotherapy cycle</description>
    <arm_group_label>MabionCD20®</arm_group_label>
    <arm_group_label>MabThera®</arm_group_label>
    <other_name>Hydroxydaunorubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>1.4 mg of vincristine per square meter, up to a maximal dose of 2 mg, administrated IV on day 1 of each chemotherapy cycle</description>
    <arm_group_label>MabionCD20®</arm_group_label>
    <arm_group_label>MabThera®</arm_group_label>
    <other_name>Oncovine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>750 mg of cyclophosphamide per square meter of body-surface area administrated IV on day 1 of each chemotherapy cycle</description>
    <arm_group_label>MabionCD20®</arm_group_label>
    <arm_group_label>MabThera®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>100 mg of prednisone administrated PO per day for five days, day 1-5 of each chemotherapy cycle</description>
    <arm_group_label>MabionCD20®</arm_group_label>
    <arm_group_label>MabThera®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histological confirmed CD20 (cluster of differentiation 20) positive
             diffuse large B cell lymphoma (DLBCL)

          2. Patients that had been diagnosed according to the WHO classification;

          3. Performance status ≤ 2 on the ECOG (Eastern Cooperative Oncology Group) / WHO (world
             Health Organization) scale, performance status of 3 will be accepted if impairment is
             caused by DLBCL complications and improvement is expected once therapy is initiated;

        Exclusion Criteria:

          1. Life expectance less than 6 months;

          2. Any chemotherapy, radiotherapy, immunotherapy, biologic, investigational or hormonal
             therapy for treatment of lymphoma within 28 days prior to treatment;

          3. Rituximab, other anti-CD20 mAb (Monoclonal Antibodies) drug treatment, treatment with
             any cell depleting therapies - e.g., anti-CD4 (cluster of differentiation 4) anti-CD5
             (cluster of differentiation 5), anti-CD3 (cluster of differentiation 3), anti-CD19
             (cluster of differentiation 19), anti CD11 (cluster of differentiation 11), anti-CD22
             (cluster of differentiation 11), BLys/BAFF (B Lymphocyte Stimulator/B-cell activating
             factor) within 1,5 years before screening;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Katarzyna Bartosik</last_name>
    <phone>+48 42 207 78 90</phone>
    <email>k.bartosik@mabion.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Magdalena Szkup</last_name>
    <phone>+48 42 207 78 90</phone>
    <email>m.szkup@mabion.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Clinical Center Banja Luka</name>
      <address>
        <city>Banja Luka</city>
        <zip>78 000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinical Center Sarajevo</name>
      <address>
        <city>Sarajevo</city>
        <zip>71 000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinical Center Tuzla</name>
      <address>
        <city>Tuzla</city>
        <zip>75 000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>General Hospital Zenica</name>
      <address>
        <city>Zenica</city>
        <zip>72 000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>GH &quot;dr.Josip Bencevic&quot;</name>
      <address>
        <city>Slavonski Brod</city>
        <zip>35000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH Merkur</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHC Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>S. Khechinashvili state University clinic</name>
      <address>
        <city>Tbilisi</city>
        <zip>0179</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HEMA</name>
      <address>
        <city>Tibilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medulla - Chemotherapy and Immunotherapy Clinic</name>
      <address>
        <city>Tibilisi</city>
        <zip>0186</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut of Oncology, Hematology Department</name>
      <address>
        <city>Chisinau</city>
        <zip>2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny w Legnicy, Oddział Hematologiczny</name>
      <address>
        <city>Legnica</city>
        <zip>59-220</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny nr1, Klinika Hematologii i Transplantacji Szpiku</name>
      <address>
        <city>Lublin</city>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewódzki w Opolu, Oddział Hematologii i Onkologii Hematologicznej</name>
      <address>
        <city>Opole</city>
        <zip>45-061</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+48 774433678</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MTZ Clinical Research Sp. Z o.o.</name>
      <address>
        <city>Warsaw</city>
        <zip>02-106</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Zemun</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Zvezdara</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Military Hospital Academy</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Public utility &quot;Chernivtsi regional clinical oncology dispensary&quot;, Day patient department</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58013</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Municipal Institution &quot;Dnipropetrovsk City multi-field Clinical Hospital #4&quot;, Oncology and medical radiology department</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital of Ivano-Frankivsk, Hematology Department.</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Oncology Dispensary, Chemotherapy Department</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kharkiv Regional Clinical Oncology Centre, Deartment of haematology</name>
      <address>
        <city>Kharkiv</city>
        <zip>61070</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>N</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Institute of Cancer, Department of chemotherapy</name>
      <address>
        <city>Kiev</city>
        <zip>03022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kiev City Clinical Oncological Center, Department of chemotherapy #2</name>
      <address>
        <city>Kiev</city>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Utility Enterprise &quot;Kirovograd regional oncology dispensary&quot;</name>
      <address>
        <city>Kirovograd</city>
        <zip>25011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kryvyi Rih Oncology Dispensary, Dnipropetrovsk Highway</name>
      <address>
        <city>Krivoy Rog</city>
        <zip>50048</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Volyn' Regional clinical hospital, Haematology Department</name>
      <address>
        <city>Lutsk</city>
        <zip>45634</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>State institution &quot;Institute for haemotopathology and haemotransfusion of National Academy of science of Ukraine</name>
      <address>
        <city>Lviv</city>
        <zip>79044</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mykolayiv Region Clinical Hospital, Heamotology department</name>
      <address>
        <city>Mykolayiv</city>
        <zip>54058</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Poltava regional oncology hospital, heamotherapy department</name>
      <address>
        <city>Poltava</city>
        <zip>36011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional clinical Hospital named after Novak, Hematology Department</name>
      <address>
        <city>Uzhgorod</city>
        <zip>88000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vinnitsya Regional Clinical Oncology Dispensary, Chemotherapy Department,</name>
      <address>
        <city>Vinnitsya</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Oncology dispensary</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69040</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zaporizhzhya Regional Clinical Hospital, Deartment of haematology and intensive therapy</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Bosnia and Herzegovina</country>
    <country>Croatia</country>
    <country>Georgia</country>
    <country>Moldova, Republic of</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>Hungary</country>
    <country>Romania</country>
  </removed_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2015</study_first_submitted>
  <study_first_submitted_qc>November 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2015</study_first_posted>
  <last_update_submitted>June 1, 2016</last_update_submitted>
  <last_update_submitted_qc>June 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

